TY - JOUR T1 - Super-Spreader Businesses and Risk of COVID-19 Transmission JF - medRxiv DO - 10.1101/2020.05.24.20112110 SP - 2020.05.24.20112110 AU - Ashley O’Donoghue AU - Tenzin Dechen AU - Whitney Pavlova AU - Michael Boals AU - Garba Moussa AU - Manvi Madan AU - Aalok Thakkar AU - Frank J. DeFalco Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/25/2020.05.24.20112110.abstract N2 - Purpose The United States has the highest number of confirmed COVID-19 cases in the world to date, with over 94,000 COVID-19-related deaths1. The true risk of a COVID-19 resurgence as states prepare to reopen businesses is unknown. This paper aims to classify businesses by their risk of transmission and quantify the relationship between the density of super-spreader businesses and COVID-19 cases.Methods We constructed a COVID-19 Business Transmission Risk Index based upon the frequency and duration of visits and square footage of businesses pre-pandemic in 2019 in 8 states (Massachusetts, Rhode Island, Connecticut, New Hampshire, Vermont, Maine, New York, and California). We used this index to classify businesses as super-spreaders. Then, we analyzed the association between the density of super-spreader businesses in a county and the rate of COVID-19 cases. We performed significance testing using a negative binomial regression. The main outcome of interest is the cumulative number of COVID-19 cases each week.Results We found a positive association between the density of super-spreader businesses and COVID-19 cases. A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases, all else equal.Conclusion Higher densities of super-spreader businesses are associated with higher rates of COVID-19 cases. This may have important implications for how states reopen super-spreader businesses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Johns Hopkins University COVID-19 data and the New York Times COVID-19 data are publically-available, linked below. SafeGraph's Monthly Patterns data and Core POI data are restricted access. The documentation for SafeGraph's datasets and the link to apply for access are linked below. https://github.com/CSSEGISandData/COVID-19 https://github.com/nytimes/covid-19-data https://docs.safegraph.com/docs/places-schema#section-patterns https://docs.safegraph.com/docs#section-core-places https://www.safegraph.com/weekly-foot-traffic-patterns ER -